Primary Outcome Measures:
- Relationship between molecular abnormalities and tumor histologic and clinical characteristics [ Time Frame: 20 Years ]
Fresh frozen, fixed and cultured tumor cells collected prospectively from a clinically well characterized patient cohort.
The overall objective of this non-therapeutic protocol is to identify molecular abnormalities within prospectively treated pediatric CNS develop xenograft and in vitro models derived from Atypical Teratoid Rhabdoid Tumors (ATRT), Choroid Plexus Carcinomas (CPC), Ependymoma and high-grade gliomas. The investigators will characterize the genome-wide mutation, expression and epigenetic signatures of these models and compare them with the primary tumors from which they were derived, thus creating well-characterized and invaluable resource for research on these rare and deadly pediatric brain tumors. This will also provide important insights into intratumoral heterogeneity, and molecular abnormalities that may influence the selective pressures driving evolution, and tumor growth as xenografts or in vitro. and define the relationship between these abnormalities and tumor histologic and clinical characteristics. This objective will be achieved by applying state-of-the-art DNA, RNA and protein epigenome analysis tools to the study of fresh frozen, fixed and cultured tumor cells and xenografts. The establishment of cell cultures from each tumor sample will also allow for in vitro and in vivo analysis of tumor cell growth, signaling and therapeutic response.